FindTrial
Sign In

To study whether a drug (Saroglitazaar) used to treat diabetes and deranged lipid profile can lead to improvement in fatty liver also

To Study The Effect Of Saroglitazar On Non-Alcoholic Fatty Liver Disease In Patients With Diabetic Dyslipidemia: An Open Longitudinal Observational Cohort Study - SAFE

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/05/019199
Enrollment
100
Registered
2019-05-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

None listed

Sponsors

Dept of Gastroenterology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 18-70 years 2. Diabetes and Dyslipidemia requiring medical treatment

Exclusion criteria

Exclusion criteria: 1. Chronic viral hepatitis 2. Significnt alcohol intake 3. Uncontrolled thyroid disease 4. Active cardio-pulmonary disease. 5. Current/past history of malignancy. 6. Chronic liver disease or chronic kidney disease (CKD).

Design outcomes

Primary

MeasureTime frame
Effect of Saroglitazar on liver enzymes in patients with diabetic dyslipidemia.Timepoint: 24 weeks—

Secondary

MeasureTime frame
Effect of Saroglitazaar on transient elastographyTimepoint: 24 weeks—

Countries

India

Contacts

Public ContactDr Omesh Goyal

Dayanand Medical College and Hospital

goyalomesh@yahoo.co.in9914821155

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026